RxDoctor Payments Data

Nina Asrani, MD

Cardiovascular Disease · Fort Worth, TXNPI 1922210939

Payments from drug & device makers

$46,794in general payments, 2019–2025

Across 97 payments — averaging $482.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$44K
  • Baxter Healthcare$1K
  • E.r. Squibb & Sons, L.L.C.$384
  • Novartis$181
  • Amgen$144
  • Boston Scientific$138
  • plus $597 from 11 others

What the payments were for

  • Food & beverage$1,51851%
  • Other$1,44949%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,794 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$210,388
Medicare patients
659
Services billed
1,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$413,129
Repatha SureclickEvolocumab61$58,443
JardianceEmpagliflozin36$46,867
XareltoRivaroxaban46$46,423
EntrestoSacubitril/Valsartan27$27,501
Dabigatran EtexilateDabigatran Etexilate Mesylate12$5,557
Metoprolol Succinate281$4,705
Ranolazine ErRanolazine21$3,066
Rosuvastatin Calcium149$2,125
Atorvastatin Calcium145$1,412
Amiodarone Hcl45$1,214
Dofetilide11$1,168
Flecainide Acetate21$988
Losartan Potassium120$956
Carvedilol77$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$413,129381 claims
Boehringer IngelheimJardiance$112$46,86736 claims
Johnson & JohnsonXarelto$14$46,42346 claims
NovartisEntresto$181$27,50127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →